ESMO

Rybrevant-Leclaza Combo Outperforms Tagrisso in EGFR-Mutant Advanced NSCLC

October 24th 2023, 3:00pm

Article

Patients with advanced non-small cell lung cancer with an EGFR mutation had a greater risk reduction for disease progression with frontline Rybrevant plus Leclaza compared with Tagrisso alone.

Enhertu Shows Survival Improvements For Patients With Mestastatic Breast Cancer

October 24th 2023, 1:00pm

Article

Central nervous system progression-free survival was shown to improve with Enhertu than with alternative treatments for patients with HER2-positive metastatic breast cancer and brain metastases.

Presurgical Keytruda Plus Chemotherapy Improves Response for Some With Breast Cancer

October 23rd 2023, 10:00pm

Article

Neoadjuvant Keytruda plus chemotherapy followed by adjuvant Keytruda plus endocrine therapy generated a statistically significant increase in pathologic complete response compared to pre-surgical placebo and chemotherapy followed by adjuvant Keytruda and endocrine therapy for patients with high-risk, early-stage, estrogen receptor–positive, HER2-negative breast cancer.

Pluvicto Improves Survival Without Progression in Certain Patients With Prostate Cancer

October 23rd 2023, 9:00pm

Article

Patients with metastatic castration-resistant prostate cancer who were never treated with a taxane derived a progression-free survival benefit from treatment with Pluvicto.

Dato-DXd Betters Progression-Free Survival in Metastatic Breast Cancer Group

October 23rd 2023, 7:00pm

Article

Dato-DXd lengthened the average time it took patients with HR-positive, HER2-low or -negative metastatic breast cancer to experience disease progression, study results showed.

Keytruda Plus Xtandi Showed No Improvements in Prostate Cancer Subset

October 23rd 2023, 1:00pm

Article

The addition of Keytruda to Xtandi showed no improvements for radiographic progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer.

Chemo Before Chemoradiation Boosts Cervical Cancer Outcomes

October 23rd 2023, 12:04am

Article

Platinum-based chemotherapy, when administered before chemoradiotherapy, improved progression-free and overall survival for patients with locally advanced cervical cancer.

Padcev Plus Keytruda Reduces Risk of Death, Disease Progression in Advanced Bladder Cancer

October 22nd 2023, 11:08pm

Article

For the first time, a drug combination (Padcev plus Keytruda) outperformed frontline chemotherapy for patients with locally advanced or metastatic urothelial carcinoma.

Lumakras Plus Vectibix Improves PFS in Colorectal Cancer

October 22nd 2023, 10:07pm

Article

The combination of Lumakras and Vectibix led to better progression-free survival compared with standard of care in patients with chemorefractory metastatic colorectal cancer harboring KRAS G12C mutations.

Tivdak Confers 30% Reduction in Mortality Risk in Cervical Cancer

October 22nd 2023, 9:01pm

Article

A 30% reduction in the risk of death versus. investigator’s choice of chemotherapy as second or third line therapy was concluded when Tivdak was combined for the treatment of recurrent or metastatic cervical cancer with disease progression on doublet chemotherapy.